PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
October 11 2023 - 12:00PM
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology
company pioneering the discovery and development of small molecule,
tumor-agnostic therapies targeting p53, today announced that it
will present updated Phase 1 data from the ongoing Phase 1/2
PYNNACLE study of PC14586 in a late-breaking poster session at the
2023 AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics, taking place October 11-15, 2023, in
Boston, Massachusetts. The poster will contain updated clinical
data from the study as of September 5, 2023.
The abstract, containing data with a May 1, 2023
cutoff, was published today and is available for conference
registrants on the AACR-NCI-EORTC 2023 Conference app.
Poster presentation
details:
Title: |
Updated Phase
1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective
p53 reactivator, in patients with advanced solid tumors harboring a
TP53 Y220C mutation |
Session Date and Time: |
12:30 PM –
4:00 PM ET on Thursday, October 12, 2023 |
Session Title: |
Poster
Session A |
Lead
Author: |
Alison M.
Schram, M.D., Memorial Sloan Kettering Cancer Center |
Abstract Number: |
LB_A25 |
Additional PC14586 Presentations at
AACR-NCI-EORTC ConferenceThe updated PYNNACLE clinical
trial data will also be discussed by
Leila Alland, M.D.,
Chief Medical Officer of PMV Pharma,
during the Chemistry in Cancer Research Town Hall at 6:00 PM ET on
Friday, October 13, 2023, and by Aparna Parikh, M.D, M.S.,
Director of the Global Cancer Care Program at Mass General
Hospital Cancer Center, as part of
Concurrent Session 8: Targeted and Immunotherapy Approaches Against
p53 at 10:00 AM ET on Saturday, October 14, 2023.
KOL Webinar
PMV will host a KOL webinar via
webcast on Thursday, October 12, 2023 at 4:00 PM
ET to review the data and to provide a regulatory update.
The event will feature presentations by Dr. Parikh
and by PMV management.
To register for the event please click here.
About the PYNNACLE Clinical
TrialThe ongoing Phase 1/2 PYNNACLE study is evaluating
PC14586 in patients with advanced solid tumors harboring a p53
Y220C mutation. The primary objective of the Phase 1 portion of the
trial is to determine the maximum tolerated dose (MTD), and
recommended Phase 2 dose (RP2D) of PC14586 when administered orally
to patients. Safety, tolerability, pharmacokinetics and effects on
biomarkers will also be assessed. Phase 2 will be an expansion
study with the primary objective of evaluating the efficacy of
PC14586 at the RP2D in patients with TP53 Y220C advanced solid
tumors. For more information about the Phase 1/2 PYNNACLE clinical
trial, refer to www.clinicaltrials.gov (NCT study identifier
NCT04585750).
About PC14586PC14586 is a
first-in-class, small molecule, p53 reactivator designed to
selectively bind to the pocket present in the p53 Y220C mutant
protein, hence, restoring the wild-type, or normal, p53 protein
structure and tumor-suppressing function. The U.S. Food and Drug
Administration (FDA) granted Fast Track designation to PC14586 for
the treatment of patients with locally advanced or metastatic solid
tumors that have a p53 Y220C mutation.
About PMV PharmaPMV Pharma is a
precision oncology company pioneering the discovery and development
of small molecule, tumor-agnostic therapies targeting p53. p53
mutations are found in approximately half of all cancers. The field
of p53 biology was established by our co-founder Arnold Levine,
Ph.D., when he discovered the p53 protein in 1979. Bringing
together leaders in the field to utilize more than four decades of
p53 biology, PMV Pharma combines unique biological understanding
with pharmaceutical development focus. PMV Pharma is headquartered
in Princeton, New Jersey. For more information, please
visit www.pmvpharma.com.
Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding the Company’s future plans or expectations for
PC14586, including the timing of disclosures regarding clinical
data updates of its current clinical trial for PC14586 and
initiation of the potentially pivotal Phase 2 portion of the study,
ongoing safety and response rate of participants in our clinical
trials, as well as the overall success of the current and future
clinical trials for PC14586, and the adequacy of the data to
support its regulatory approval, and any future commercialization
plans for the product candidate; and the future plans or
expectations for the Company’s discovery platform for its other
early-stage and clinical candidates. Any forward-looking statements
in this statement are based on management’s current expectations of
future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those set forth in or implied by such
forward-looking statements. Risks that contribute to the uncertain
nature of the forward-looking statements include: the success,
cost, and timing of the Company’s product candidate development
activities and planned clinical trials, the Company’s ability to
execute on its strategy and operate as an early clinical stage
company, the potential for clinical trials of PC14586 or any future
clinical trials of other product candidates to differ from
preclinical, preliminary or expected results, the Company’s ability
to fund operations, and the impact that the current COVID-19
pandemic will have on the Company’s clinical trials, supply chain,
and operations, as well as those risks and uncertainties set forth
in the section entitled “Risk Factors” in the Company’s Annual
Report on Form 10-K filed with the Securities and Exchange
Commission (the “SEC”) on March 1, 2023 and its other filings filed
with the SEC. All forward-looking statements contained in this
press release speak only as of the date on which they were made.
The Company undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Contacts
Investor Contact:
Winston KungPMV Pharmaceuticals, Inc.investors@pmvpharma.com
Media Contact:
Kathy VincentGreig
Communicationskathy@greigcommunications.com
PMV Pharmaceuticals (NASDAQ:PMVP)
Historical Stock Chart
From Sep 2024 to Oct 2024
PMV Pharmaceuticals (NASDAQ:PMVP)
Historical Stock Chart
From Oct 2023 to Oct 2024